DarioHealth Announces Two New Studies Presented At ADA Scientific Sessions; Research Confirms Sustainable Behavior Change Over 12 Months With Dario Digital Platform; 31% Of Dario Members With Type 2 Diabetes Achieve Diabetes Remission; Analysis Includes Members Tracking GLP-1 Medication

6/25/24 8:31:23 AM ET

Medical/Dental Instruments

Health Care

Get the next $DRIO alert in real time by email

Get the next $DRIO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DRIO

Date	Price Target	Rating	Analyst
5/13/2022	$8.75	Neutral → Buy	Alliance Global Partners
1/26/2022	$28.00 → $25.00	Buy	Aegis Capital
8/19/2021	$35.00 → $28.00	Buy	Aegis Capital

More analyst ratings

Dario Signs Four New Employer Contracts Across Full Product Suite
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK, Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025. The contracts s
11/21/24 8:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care
DarioHealth Reports Third Quarter 2024 Financial and Operating Results
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
11/7/24 6:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care
Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population
The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK, Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions. The launch with this new health plan marks the third Medicaid client for Dario, continuing a solid momentum within the Medicaid space. The newly signed health plan, familiar with Dario's results with another regional health plan, chose Dario based on the Company's success and reputation for
10/30/24 8:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care

DarioHealth Reports Third Quarter 2024 Financial and Operating Results
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
11/7/24 6:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care
DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th
Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal
10/23/24 8:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care
DarioHealth Reports Second Quarter 2024 Financial and Operating Results
Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,
8/8/24 6:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care

$DRIO
Leadership Updates

Live Leadership Updates

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
10/28/24 4:44:00 PM ET
$BMY
$DRIO
$NVS
$OSTX
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments
Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
6/5/24 8:30:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care
Digital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer
Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms. Dario also
4/4/23 8:00:00 AM ET
$DRIO
Medical/Dental Instruments
Health Care

DarioHealth Announces Two New Studies Presented At ADA Scientific Sessions; Research Confirms Sustainable Behavior Change Over 12 Months With Dario Digital Platform; 31% Of Dario Members With Type 2 Diabetes Achieve Diabetes Remission; Analysis Includes Members Tracking GLP-1 Medication

Chat with this insight

Recent Analyst Ratings for $DRIO

$DRIO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

$DRIO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

$DRIO Market Insights

Live Market Insights

Dario Expands GLP-1 Solution Client Base With New Employer Contract; Financial Terms Not Disclosed

DarioHealth Announces Two New Studies Presented At ADA Scientific Sessions; Research Confirms Sustainable Behavior Change Over 12 Months With Dario Digital Platform; 31% Of Dario Members With Type 2 Diabetes Achieve Diabetes Remission; Analysis Includes Members Tracking GLP-1 Medication

DarioHealth Q1 Net Loss $(7.2)M Compared To $(12.8)M YoY

$DRIO Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by DarioHealth Corp.

SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

$DRIO SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by DarioHealth Corp.

SEC Form 10-Q filed by DarioHealth Corp.

SEC Form DEF 14A filed by DarioHealth Corp.

$DRIO Press Releases

Fastest customizable press release news feed in the world

$DRIO Financials

Live finance-specific insights

$DRIO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dario Signs Four New Employer Contracts Across Full Product Suite

DarioHealth Reports Third Quarter 2024 Financial and Operating Results

Dario Signs New Regional Health Plan, Expanding Reach in Medicaid Population

DarioHealth Reports Third Quarter 2024 Financial and Operating Results

DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th

DarioHealth Reports Second Quarter 2024 Financial and Operating Results

DarioHealth upgraded by Alliance Global Partners with a new price target

Aegis Capital reiterated coverage on DarioHealth with a new price target

Aegis Capital reiterated coverage on DarioHealth with a new price target

$DRIO Leadership Updates

Live Leadership Updates

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

Digital Health Product Leader, Eitan Shay, Joins Dario as Chief Product Officer

Recent Analyst Ratings for
$DRIO

$DRIO
Insider Purchases

$DRIO
Insider Trading

$DRIO
Market Insights

$DRIO
Large Ownership Changes

$DRIO
SEC Filings

$DRIO
Press Releases

$DRIO
Financials

$DRIO
Analyst Ratings

$DRIO
Leadership Updates